Cantor Fitzgerald Reiterates Overweight on Arcutis Biotherapeutics, Maintains $50 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Arcutis Biotherapeutics (NASDAQ:ARQT) and maintained a $50 price target.
June 28, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Arcutis Biotherapeutics and maintained a $50 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Arcutis Biotherapeutics. The maintained price target of $50 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100